Influence of psychosocial risk factors on the course and prognosis of cardiovascular diseases

It has now been established that psychosocial risk factors significantly worsen the course of cardiovascular diseases (CVDs) and reduce patients’ adherence to treatment. Patients with CVDs are characterized by a high prevalence of anxiety comorbidities, which can reach 50-60%. The presence of concomitant anxiety disorders seriously worsens the prognosis of CVDs. The results of studies showed that anxiety increases the risk of fatal myocardial infarction and sudden death by 1,9 times and 4,5 times, respectively. Therefore, the correction of psychosocial factors, in particular anxiety symptoms, should be an important component of the treatment of patients with CVDs. The conducted studies show that the use of fabomotizole in patients with CVD and concomitant anxiety disorders reduces the anxiety manifestations. In addition, a pronounced improvement of somatic status is recorded, which is important for improving the course and prognosis of CVDs. The accumulated experience of fabomotizole use makes it possible to recommend it for the treatment of patients with anxiety and CVDs.

1. Cardiovascular prevention 2017. National guidelines. Russian Journal of Cardiology. 2018;(6):7-122. (In Russ.) doi:10.15829/1560-4071-2018-6-7-122. EDN XSLTTF.

2. Somers JM, Goldner EM, Waraich P, Hsu L. Prevalence and incidence studies of anxiety disorders: a systematic review of the literature. Can J Psychiatry. 2006;51(2):100-13. doi:10.1177/070674370605100206.

3. Davydov AT, Litvintsev SV, Butko DYu, et al. Experience in the diagnosis and treatment of anxiety disorder in the post-stroke period in patients who have suffered an ischemic stroke. Russian Medical Journal. 2008;16(5):266-9. (In Russ.)

4. Khaustova EA, Bezsheiko VG. Modern ideas about the diagnosis and therapy of anxiety disorders. International Neurological Journal. 2012;2(48):52-60. (In Russ.)

5. Krasnov VN, Dovzhenko TV, Bobrov AE. Anxiety and depressive disorders in patients of the primary medical network. Medical Bulletin. 2010;11(516):9-10. (In Russ.)

6. Smulevich AB. Psychosomatic disorders in clinical practice. Moscow time: MEDpress-inform. 2019. (In Russ.)

7. Belyalov FI. Depression, anxiety and stress in patients with coronary heart disease. Therapeutic Archive. 2017;89(8):104-9. (In Russ.) doi:10.17116/terarkh2017898104-109. EDN: ZFDKYH.

8. Pogosova G. V. Anxiety states in cardiac patients: diagnostics and treatment aspects. Cardiovascular Therapy and Prevention. 2006;5(5):75-80. (In Russ.)

9. Ibatov AD. The influence of anxiety disorders on the course of coronary heart disease. Russian Medical Journal. 2007;15(20):1443-6. (In Russ.)

10. Vanchakova NP. Anxiety disorders in patients with hypertension and coronary heart disease and their correction by tenoten. Polyclinic. 2007;2:56-60. (In Russ.)

11. Pogosova NV, Boitsov SA, Oganov RG, et al. Clinical and epidemiological program for the study of psychosocial risk factors in cardiological practice in patients with arterial hypertension and coronary heart disease (COMET): the first results of a Russian multicenter study. Cardiology. 2018;58(9):4758. (In Russ.) doi:10.18087/cardio.2018.9.10171.

12. Shalnova SA, Evstifeeva SE, Deev AD, et al. The prevalence of anxiety and depression in various regions of the Russian Federation and its association with socio-demographic factors (according to the ESSAY-RF study). Therapeutic Archive. 2014;86(12):53-60. (In Russ.) doi:10.17116/terarkh2014861253-60.

13. Kubzansky LD, Kawachi I. Going to the heart of the matter: do negative emotions cause coronary heart disease? J Psychosom Res. 2000;48(4-5):323-37. doi:10.1016/s0022-3999(99)00091-4.

14. Kopylov FYu, Syrkin AL, Drobizhev MYu, et al. Clinical and psychosomatic features of the course of hypertension in conditions of chronic stress. Clinical medicine. 2008;2:23-5. (In Russ.)

15. Borovkov N, Berdnikova L, Dobrotina I. On the treatment of anxiety and depressive disorders in patients with cardiovascular diseases. Doctor. 2013;(12):53-8. (In Russ.)

16. Kalinina SYu, Zhulina NI, Belova AN, Suvorov AV. The effect of the anxiolytic Afobazole on the effectiveness of treatment of hypertension in elderly women. Review of Psychiatry and Medical Psychology named after V. M. Bekhterev. 2009;(4):3741. (In Russ.)

17. Eaker ED, Pinsky J, Castelli WP. Myocardial infarction and coronary death among women: psychosocial predictors from a 20-year follow-up of women in the Framingham Study. Am J Epidemiol. 1992;135:854-64. doi:10.1093/oxfordjournals.aje.a116381.

18. Shen B-J, Avivi YE, Todaro JF, et al. Anxiety characteristics independently and prospectively predict myocardial infarction in men. The unique contribution of anxiety among psychologic factors. J Am Coll Cardiol. 2008;51(2):113-9. doi:10.1016/j.jacc.2007.09.033.

19. Kubzansky LD, Kawachi I, Spiro A, et al. Is worrying bad for your heart? A prospective study of worry and coronary heart disease in the Normative Aging Study. Circulation. 1997;95:818-24. doi:10.1161/01.cir95.4.818.

20. Starostina EG. Generalized anxiety disorder and symptoms of anxiety in general medical practice. Russian Medical Journal. 2004;(22):1277-83. (In Russ.)

21. Moser DK. “The rust of life”: impact of anxiety on cardiac patients. Am J Crit Care. 2007;16(4):361-9.

22. Syunyakov TS, Neznamov GG. Evaluation of the therapeutic efficacy and safety of the selective anxiolytic afobazole in generalized anxiety disorder and adjustment disorders: Results of a multicenter randomized comparative study of diazepam. Terapevticheskii arkhiv. 2016;88(8):73-86. (In Russ.) doi:10.17116/terarkh201688873-86.

23. Medvedev VE, Trosnova AP, Dobrovolsky AV. Psychopharmacotherapy of anxiety disorders in patients with cardiovascular diseases: the use of afobazole. Journal of Neurology and Psychiatry. 2007;107(7):25-9. (In Russ.)

24. Tatarsky BA, Biserova IN. The use of Afobazole in the treatment of paroxysmal atrial fibrillation. Russian Medical Journal. 2007;(9):760-6. (In Russ.)

25. Zhidkikh BD, Kolesnikova OE, Barbashina TA, et al. The effect of Afobazole on the quality of life of cardiac patients during inpatient treatment. Russian Medical Journal. 2007;15(16):1241-5. (In Russ.)

26. Zhidkikh BD. The effectiveness of Afobazole in the treatment of cardiac patients. Doctor. 2014;(8):32-7. (In Russ.)

27. Podkhomutnikov VM. The use of Afobazole in patients with myocardial infarction. Consilium medicum. Mental disorders in general medicine. 2007;2(4):35-6. (In Russ.)

28. Petrova NN. Anxiety disorders and their correction in outpatient psychiatric practice. Psychiatry and psychopharmacotherapy. 2011;13(6):30-5. (In Russ.)

29. Gorshunova NK, Ukraintseva DN. Treatment of anxiety in patients of older age groups: clinical efficacy of the use of anxiolytics of the non-benzodiazepine series of Afobazole. Directory of polyclinic doctor. 2007;(3):70-4. (In Russ.)

30. Svishchenko EP. Experience of using the drug Afobazole in patients with hypertension and panic attacks. Internal medicine. 2008;4(10). (In Russ.)

31. Chumakova EA, Gaponova NI, Berezina TN. Afobazole effectiveness in the complex treatment of patients with arterial hypertension. Russian Journal of Cardiology. 2014;(2):8995. (In Russ.) doi:10.15829/1560-4071-2014-2-89-95.

32. Melnik MG, Kanorsky SG, Bogdanova OA, Trubchaninova SA. Evaluation of short-term effects of Afobazole in geriatric patients with combined psychosomatic diseases. Psychiatry and psychopharmacotherapy. 2014;16(4):46-51. (In Russ.)

33. Medvedev VE. Therapy of anxiety-depressive disorders in patients with therapeutic profile. Psychiatry and psychopharmacotherapy. 2015;17(1):22-30. (In Russ.)